Avelumab (Bavencio): Uses and Availability in India

Avelumab is a fully human monoclonal antibody that blocks PD-L1, a protein carried on the surface of many cancer cells. PD-L1 normally switches off the T cells that would otherwise attack the tumour. Blocking it aims to let those T cells work again. Bavencio is the brand name; avelumab is the molecule inside it.

Most checkpoint inhibitors an Indian patient meets — pembrolizumab, nivolumab, cemiplimab — block PD-1, the receptor on the T cell. Avelumab blocks the other half of the same handshake, PD-L1, on the tumour side. The practical effect is similar. The distinction matters mainly when you are holding a prescription and cannot find your drug described in anything you have read about PD-1 medicines.

It was developed by Merck KGaA of Darmstadt in alliance with Pfizer. The US Food and Drug Administration first approved it on 23 March 2017. In the European Union, Bavencio received a conditional marketing authorisation on 18 September 2017, which was switched to a full marketing authorisation on 19 August 2020.

Two things follow from the mechanism. First, avelumab does not attack cancer cells directly the way chemotherapy does. It works only where the person still has T cells able to respond, which is why it helps in a proportion of patients rather than in everyone who receives it. Second, taking a brake off the immune system can let that system turn on healthy organs. That is where immune-related adverse events come from, and they are covered further down this page.

It is not an immunity booster, not a general tonic, and not something that can be added to another treatment plan without the treating team knowing.

Mechanism and authorisation dates here follow the European Medicines Agency public medicine overview for Bavencio and the US FDA approval record.

Three, and the list is short. Metastatic Merkel cell carcinoma, a rare and aggressive skin cancer, on its own. Advanced bladder cancer, as first-line maintenance after platinum chemotherapy. And advanced kidney cancer, in combination with axitinib. It is not a general cancer treatment.

Two of those three are why most people arrive at this page, and both are unusual. Merkel cell carcinoma is rare enough that avelumab became the first medicine approved anywhere for it, in March 2017. Bladder maintenance is unusual in a different way: the medicine starts when chemotherapy stops, which is not how most cancer drugs are used, and it causes more confusion than any other part of the label.

How often does the tumour actually respond?

The European Medicines Agency publishes the response figures behind the Merkel cell authorisation. In the main study of 88 adults who had already been treated, the cancer shrank or was no longer detectable in around 33%, and in most of those the response lasted at least six months. In a separate group of 116 people with metastatic Merkel cell carcinoma who had not had chemotherapy in the previous six months, the overall response rate was around 40%.

Read those numbers honestly. They are response rates in selected trial populations, reported by a regulator, and they describe tumour shrinkage rather than a promise about any individual. They also mean that in each group, a substantial share of the people treated did not have their tumour shrink. No page can tell you which group you would be in. Your own oncologist, working from your reports, is the only person who can weigh that.

Maintenance means the medicine starts after chemotherapy has finished, not alongside it. In advanced bladder cancer, avelumab is given to people whose disease has not progressed on four to six cycles of platinum chemotherapy. Treatment begins four to ten weeks after the last chemotherapy dose and continues until the disease progresses or side effects make it unsafe.

Oncologists call this switch maintenance, and it is the single most misread part of this drug's label. Four things follow from it, and each one changes what a family should expect.

• It is not a rescue after progression. Maintenance is for people whose cancer responded to chemotherapy or stayed stable on it. If the disease grew during platinum chemotherapy, this is not the setting, and a different conversation is needed.
• It is not given with chemotherapy. Nothing is added to the chemotherapy cycles themselves. The medicine starts in the gap after them, which is why it can feel to a patient like starting treatment all over again just as they had finished.
• The window matters. The trial behind the approval started patients four to ten weeks after their last chemotherapy dose. Oncology teams therefore treat that gap as a scheduling deadline rather than a suggestion, and a delay in scans or reports can genuinely close it.
• It is open-ended. There is no fixed number of cycles. Treatment continues while it appears to be working and is tolerated, reviewed at each scan, which makes the financial planning different from a course with a defined stopping point.

The evidence behind the setting is straightforward to state without overselling it. The US FDA converted avelumab's earlier accelerated bladder-cancer approval into a regular approval on 30 June 2020 on the strength of JAVELIN Bladder 100, a randomised trial of 700 people that compared maintenance avelumab plus best supportive care against best supportive care alone. Guideline bodies have since treated first-line maintenance after platinum chemotherapy as a standard consideration in this population.

Whether it applies to you depends on how your own cancer responded to chemotherapy and on your oncologist's assessment of your reports — not on the fact that you had platinum chemotherapy.

Yes, on publicly available information as of August 2026. Avelumab appears on the CDSCO public approved-drugs listing as a 20 mg/mL concentrate for solution for infusion under the Bavencio name, and Indian pharmacy listings show a 200 mg / 10 mL vial marketed here by Merck Ltd. Stocking is another matter — confirm it with the treating hospital's pharmacy.

Being approved and being on the shelf are not the same thing. Avelumab is a low-volume medicine in India because its indications are narrow: metastatic Merkel cell carcinoma is rare, and bladder maintenance applies only to the subset of patients whose disease did not progress on chemotherapy. Hospitals therefore tend to order it in rather than hold stock, which usually adds days. That is a very different problem from a checkpoint inhibitor that is not marketed in India at all, where a named-patient import can take weeks.

It is a cold-chain product, stored between 2 and 8°C and never frozen. A break in that chain is not visible in the vial, which is why documented handling matters more here than it does for a tablet.

Counterfeit checkpoint inhibitors have been reported entering the Indian market. Insist that any vial is dispensed through a licensed hospital pharmacy with a verifiable batch record and documented cold-chain handling, and refuse a loose vial offered outside that chain, whatever the saving. How to check an immunotherapy vial is genuine sets out what to look at before a vial is opened.

A manufacturer-linked patient support programme has been advertised for this medicine in India. What such programmes cover changes over time, and the hospital pharmacy or the prescribing oncologist is the right place to establish the current position for a specific case.

As a drip into a vein, in a day-care unit. The standard adult dose is a flat 800 mg every two weeks, infused over about 60 minutes. Before each of the first four infusions, an antihistamine and paracetamol are given to reduce the risk of an infusion reaction. There is no tablet, and no version that can be taken at home.

Three features set the practical rhythm of this medicine apart from most other checkpoint inhibitors, and all three have consequences for a family's calendar and budget.

• A fortnightly schedule, not three-weekly. Pembrolizumab and cemiplimab are given every three weeks, and pembrolizumab has a six-weekly option in some settings. Avelumab does not — it is every two weeks, which means roughly 26 hospital visits in a year rather than 17, with the travel, leave and day-care charges that implies.
• Routine premedication for the first four doses. The European Medicines Agency notes that an antihistamine and paracetamol are given before each of the first four infusions to reduce infusion-related reactions such as flushing, chills, fever, back or abdominal pain, allergic reactions and difficulty breathing. If none have occurred by the fourth infusion, the treating doctor may decide to stop the premedication.
• The dose is flat, not weight-based. 800 mg is 800 mg regardless of body weight. A 50 kg patient and a 90 kg patient use the same four vials, so a smaller patient does not pay less per dose.

What a treatment day looks like:

1. Before the cycle — blood tests check thyroid, liver, kidney and blood-count values, and you are asked about any new symptom since the last dose. Results can delay a cycle. That is routine caution, not a setback.
2. Review — the oncologist confirms the dose and that it is safe to proceed that day.
3. Premedication — an antihistamine and paracetamol, for the first four infusions.
4. The infusion — a cannula is placed and the medicine runs in over about an hour. No sedation is needed, and hair loss is not expected from this medicine itself.
5. Observation — a period of monitoring for infusion reactions, longer after the first dose.
6. Between doses — you watch for new symptoms and report them promptly. Immune side effects can appear weeks or months after a dose, and even after treatment has stopped.

The commonest reported effects are tiredness, nausea, diarrhoea, constipation, reduced appetite, vomiting, weight loss and infusion-related reactions. The characteristic risk of the class is an immune-related adverse event, where the immune system attacks a healthy organ. Most are manageable when reported early. A few are medical emergencies.

Immune-related events are defined as much by when they appear as by what they are. That is why pre-dose blood tests continue for the whole course, and why a symptom appearing weeks after a dose still counts.

Symptoms that need urgent assessment, not home management: new or worsening breathlessness or a persistent dry cough; loose motions that increase in number or contain blood; chest pain or palpitations; severe unexplained fatigue with dizziness, vomiting or collapse; yellowing of the eyes or skin; a blistering or peeling rash, or sores in the mouth or eyes. For any of these, contact your treating oncology team immediately or go to the nearest emergency department. Do not self-medicate and do not wait for the next scheduled dose. Tell any doctor who sees you, in any department, that you are on immunotherapy — it changes how these symptoms are investigated.

Detailed, symptom-by-symptom guidance sits on the dedicated side-effect pages rather than here. This page is an orientation to the medicine, not a triage tool.

Published Indian pharmacy listings put a 200 mg / 10 mL Bavencio vial at a listed maximum retail price of roughly ₹1.47 lakh, with selling prices commonly a little lower (indicative, as of August 2026). The standard 800 mg dose needs four vials, and it repeats every two weeks.

Four things drive what a course actually costs, and the vial figure is only the first.

• The fortnightly interval. Twenty-six doses in a year, against about seventeen for a three-weekly medicine. This is the largest single difference between avelumab and the PD-1 drugs most Indian families will have read about.
• The flat dose. Four 200 mg vials each time, regardless of body weight, so there is no saving for a lighter patient and no vial-sharing arithmetic to negotiate.
• No biosimilar route. There is no avelumab biosimilar in India as of August 2026. The price relief that biosimilar competition brought to nivolumab — whose Indian patent lapsed in May 2026, with a domestic biosimilar launched in January 2026 at roughly a quarter of the reference price (indicative, as of August 2026) — does not apply here.
• Everything around the infusion. Day-care charges, pre-dose blood tests and consultations, plus response-assessment PET-CT, which is generally coordinated at partner imaging centres rather than performed inside the treating unit and is billed separately.

Insurance and schemes are worth settling in writing before the first dose. Ask the insurer or the scheme desk specifically whether the drug, the day-care charge and the imaging are each covered, and for how many doses. Aarogyasri and other state-scheme packages carry their own ceilings and inclusion lists, and any figure quoted anywhere, including on this page, is indicative as of August 2026 and changes.

Avelumab is one of a group of named antibody medicines that patients meet by brand name on a prescription rather than by drug class, and the same questions come up for each of them. Rituximab: Uses, Cost and Side Effects covers the longest-established of them and the one with the widest biosimilar market in India. Trastuzumab and Trastuzumab Deruxtecan in Breast Cancer explains how a plain antibody and an antibody-drug conjugate differ, which is a distinction that trips up a lot of reading. Cetuximab and Nimotuzumab in Head and Neck Cancer sets an imported antibody against an Indian-developed one, the same availability question this page runs into.

For the full picture across checkpoint inhibitors, biosimilars, verification and cost, start from Immunotherapy Medicines Explained. For how immunotherapy works as a treatment rather than as a list of molecules, the main immunotherapy section is the place to begin.